Lynparza Patent Protection
12 patents · AstraZeneca AB
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 8143241 | Orange Book listed patent | AstraZeneca AB | Aug 12, 2027 | 1.1y left |
| 8071579 | Orange Book listed patent | AstraZeneca AB | Aug 12, 2027 | 1.1y left |
| 7449464 | Drug substance & product patent | AstraZeneca AB | Sep 8, 2027 | 1.2y left |
| 8247416 | Drug substance (composition of matter) patent | AstraZeneca AB | Sep 24, 2028 | 2.3y left |
| 11975001 | Drug product (formulation / method-of-use) patent | AstraZeneca AB | Oct 7, 2029 | 3.3y left |
| 11633396 | Drug product (formulation / method-of-use) patent | AstraZeneca AB | Oct 7, 2029 | 3.3y left |
| 12048695 | Drug product (formulation / method-of-use) patent | AstraZeneca AB | Oct 7, 2029 | 3.3y left |
| 12178816 | Drug product (formulation / method-of-use) patent | AstraZeneca AB | Oct 7, 2029 | 3.3y left |
| 12144810 | Drug product (formulation / method-of-use) patent | AstraZeneca AB | Oct 7, 2029 | 3.3y left |
| 8475842 | Drug product (formulation / method-of-use) patent | AstraZeneca AB | Dec 31, 2029 | 3.5y left |
| 8859562 | Orange Book listed patent | AstraZeneca AB | Aug 4, 2031 | 5.1y left |
| 11970530 | Orange Book listed patent | AstraZeneca AB | Oct 25, 2041 | 15.3y left |
Related Drug Patent Expirations
17 patents · earliest expires 2026 · AstraZeneca AB
5 patents · earliest expires 2032 · AstraZeneca AB
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
6 patents · earliest expires 2027 · Novartis AG
3 patents · earliest expires 2027 · Pfizer Inc.
44 patents · earliest expires 2027 · Pharmacyclics LLC
For Lynparza, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Lynparza’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.